| Name | (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol |
|---|---|
| Synonyms |
(1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
PF04971729;PF 04971729 (ERTUGLIFLOZIN) (1S,2S,3S,4R,5S)-(2,3,4-TRIS-BENZYLOXY-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL)-68-DIOXA-BICYCLO(3.2.1)OCT-1-YL)-METHANOL agliflozin 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose PF-04971729(Ertugliflozin) (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Feline Diabetes SGLT2 Inhibitor Intermediate Ertugliflozin Intermediate PF05 Leuco methylthioninium Ertugliflozin MK-8835 PF 04971 (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Ertugliflozin/PF-04971729 MK-8835, PF-04971729 Ertugliflozin, >= Ertugliflozin : PF 04971 Ertugliflozin D4 Ertugliflozin (USAN/INN) Leuco methylthioninium Impurity cc-212 Ertuglifozin ERTUGLIFLOZIN;PF04971729;PF β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl) PF-04971729/Ertugliflozin Ertugliflozin, 10 mM in DMSO PF-04971729-00 PF-04971729 //BP 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose PF-04971729/PF04971729 PF-04971729 Ertugliflozin Base 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose PF-4971729) Empagliflozin Impurity MK-8835 |
| Description | Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. A drug for the treatment of type 2 diabetes mellitus[2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.877 nM (h-SGLT2)[1]. |
| In Vitro | Ertugliflozin (PF-04971729) demonstrates >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) in vitro[3]. |
| In Vivo | Ertugliflozin (PF-04971729) reveals a concentration-dependent glucosuria after oral administration to rats[3]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 630.5±55.0 °C at 760 mmHg |
| Molecular Formula | C22H25ClO7 |
| Molecular Weight | 436.883 |
| Flash Point | 335.1±31.5 °C |
| Exact Mass | 436.128876 |
| PSA | 108.61000 |
| LogP | 6.49 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.652 |
| Storage condition | -20℃ |
|
~28%
1210344-57-2 |
| Literature: WO2010/23594 A1, ; Page/Page column 64-66 ; |
|
~%
1210344-57-2 |
| Literature: Organic Letters, , vol. 12, # 13 p. 2940 - 2943 |
| Precursor 2 | |
|---|---|
| DownStream 0 | |